Investigating the balance of opioid receptors in alcohol use disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study uses positron emission tomography (PET) imaging to measure Mu-Opioid receptors (MOR) and Kappa-Opioid receptors (KOR) in individuals with alcohol use disorder (AUD). It aims to compare receptor availability in participants with AUD during early abstinence to healthy controls, and to explore how these receptor levels relate to clinical outcomes such as craving, mood, and withdrawal. Participants will either undergo a medically supervised detoxification program or engage in outpatient abstinence with daily meetings. The study will involve 50 individuals with AUD and 50 matched healthy controls, with assessments conducted over a period of approximately six days.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with AUD will have a current diagnosis of AUD according to DSM-5 criteria (i.e., SCID-5 ascertained diagnosis, confirmed by the Principal Investigators);
* Participants with AUD will meet the following drinking criteria: males will drink \> 14 drinks per week and exceed 4 drinks per day at least twice per week; females will drink \> 7 drinks per week and exceed 3 drinks per day at least twice per week. They must meet drinking criteria during a consecutive 30-day period within the 90 days prior to intake;
* Participants with AUD will indicate willingness to abstain from alcohol and engage in a quit attempt;
* Healthy subjects will have no current or past diagnosis of AUD or other significant substance use disorder. They will drink less than 5 alcoholic drinks per week with no heavy drinking days (i.e., \>4 drinks/day for men; \>3 drinks/day for women) in the last 30 days;
* Able to read and write English and to provide voluntary, written informed consent;
* Agree to have blood drawn for genotyping of the OPRM1 which has been shown to impact the \[11C\]CFN outcome measure, BPND50.

Exclusion Criteria:

* Current significant medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology that would impact the integrity of the data (note that elevated liver enzymes for individuals with AUD will not be exclusionary);
* Past or current neurological disorder or disorders affecting the brain including but not limited to multiple sclerosis, history of stroke, brain tumors, traumatic brain injury with loss of consciousness, seizure disorder;
* Current significant psychiatric disorder including severe substance use disorder (other than alcohol or tobacco use disorders\*), and past or current psychotic symptoms;
* Regular use in the past 6 months of any prescription, psychoactive or herbal medications (e.g., antidepressants, antipsychotics, anxiolytics) that would impact the integrity of the data (e.g., naltrexone); No subject will be asked to stop taking medication to participate in the study;
* Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or her partner is surgically sterile or she is postmenopausal (hormone contraceptives \[oral, implant, injection, patch, or ring\], contraceptive sponge, double barrier \[diaphragm or condom plus spermicide\], or IUD;
* Contraindications to MRI such as claustrophobia or metal in their body;
* Subjects whose participation would cause them to exceed yearly radiation limits for research subjects

Where it's running

• Yale University
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Kelly Cosgrove, PhD — Yale University
• Study coordinator: Marc Grasso
• Email: marc.grasso@yale.edu
• Phone: 2037375083

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures

  This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.

  Recruiting Université Catholique de Louvain · Brussels, Belgium · NCT07925281

• Thiamine to reduce brain injury in adults with alcohol use disorder

  This trial tests whether thiamine can help protect the brain in adults with moderate to severe alcohol use disorder who drink daily.

  Recruiting Phase 2 Institut National de la Santé Et de la Recherche Médicale, France · Paris, Île-de-France Region · NCT07844720

• Digital Recovery Support for Black adults with Alcohol Use Disorder in Detroit

  This study tests whether a smartphone-based digital recovery program helps Black or African American adults in Detroit maintain their recovery from alcohol use disorder.

  Recruiting Brandeis University · Detroit, Michigan · NCT07724275

• Path180: a computer-based skills program to help teens reduce alcohol use

  This 8-week trial tests Path180, a computer-based skills training, added to usual care for teens 13–19 with alcohol use disorder to see if it improves daily-life coping skills and outcomes.

  Recruiting Brown University · Providence, Rhode Island · NCT07713251

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Psilocybin in Alcohol Use Disorder with Depression (Relapse Prevention)

  This study tests whether higher-dose psilocybin-assisted psychotherapy helps prevent relapse in adults with severe alcohol use disorder and depressive symptoms after detox.

  Recruiting Phase 3 Centre Hospitalier Universitaire de Nīmes · Bayonne and 7 other locations · NCT07638553

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.